SNY - Sanofi Regeneron win FDA priority review for Dupixent label expansion
2024-02-23 05:40:38 ET
Sanofi ( NASDAQ: SNY ) and partner Regeneron Pharmaceuticals ( NASDAQ: REGN ) announced Friday the receipt of priority review for their supplemental biologics license application (sBLA) for Dupixent (dupilumab), an anti-inflammatory medication....
Sanofi, Regeneron win FDA priority review for Dupixent label expansion